Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y3D9
UPID:
RT23_HUMAN
Alternative names:
28S ribosomal protein S23, mitochondrial
Alternative UPACC:
Q9Y3D9; B2R6V3; Q96Q24; Q9BWH8; Q9P053
Background:
Small ribosomal subunit protein mS23, also known as 28S ribosomal protein S23, mitochondrial, plays a crucial role in the mitochondrial ribosome. Its primary function involves participating in protein synthesis within mitochondria, essential for cellular energy production.
Therapeutic significance:
Understanding the role of Small ribosomal subunit protein mS23 could open doors to potential therapeutic strategies for treating Combined oxidative phosphorylation deficiency 46, a disorder linked to mitochondrial respiratory chain complex deficiencies.